Search Videos and More

Showing 1 - 12 of 282 results

Previous| 1 | 2 | 3 ...24 |Next


Dana-Farber Research Publication 04.01.2024 News

Dana-Farber Research Publication 04.01.2024

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Cancer Institute Launches Neuro-Inclusive Oncology Care and Empowerment Program News

Dana-Farber Cancer Institute Launches Neuro-Inclusive Oncology Care and Empowerment Program

Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).
Bispecific Antibody Therapies for Lymphoma News

Bispecific Antibody Therapies for Lymphoma

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own.
Dana-Farber Research Publication 03.15.2024 News

Dana-Farber Research Publication 03.15.2024

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice News

Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice

Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
BCL2 Inhibitors: What’s the Latest Research? News

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.
Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children News

Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children

Dana-Farber Cancer Institute's Scott Armstrong, MD, PhD, Benjamin Ebert, MD, PhD, Eric Fischer, PhD, Cigall Kadoch, PhD, and Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children.
Symposium

2024 ASCO GU Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2024.
Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List News

Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List

Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech.
Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards News

Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards

Christopher D.M. Fletcher, MD, Timothy R. Rebbeck, PhD, David Pellman, MD, and Gordon J. Freeman, PhD, will be recognized by the American Association for Cancer Research (AACR) with 2024 Scientific Achievement Awards.
Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker News

Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.
Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients

Showing 1 - 12 of 282 results

Previous| 1 | 2 | 3 ...24 |Next